112 related articles for article (PubMed ID: 20457619)
1. Mechanistic evaluation of the novel HSP90 inhibitor NVP-AUY922 in adult and pediatric glioblastoma.
Gaspar N; Sharp SY; Eccles SA; Gowan S; Popov S; Jones C; Pearson A; Vassal G; Workman P
Mol Cancer Ther; 2010 May; 9(5):1219-33. PubMed ID: 20457619
[TBL] [Abstract][Full Text] [Related]
2. The HSP90 inhibitor NVP-AUY922 potently inhibits non-small cell lung cancer growth.
Garon EB; Finn RS; Hamidi H; Dering J; Pitts S; Kamranpour N; Desai AJ; Hosmer W; Ide S; Avsar E; Jensen MR; Quadt C; Liu M; Dubinett SM; Slamon DJ
Mol Cancer Ther; 2013 Jun; 12(6):890-900. PubMed ID: 23493311
[TBL] [Abstract][Full Text] [Related]
3. HSP90 inhibition leads to degradation of the TYK2 kinase and apoptotic cell death in T-cell acute lymphoblastic leukemia.
Akahane K; Sanda T; Mansour MR; Radimerski T; DeAngelo DJ; Weinstock DM; Look AT
Leukemia; 2016 Jan; 30(1):219-28. PubMed ID: 26265185
[TBL] [Abstract][Full Text] [Related]
4. Chaperone-mediated autophagy degradation of IGF-1Rβ induced by NVP-AUY922 in pancreatic cancer.
Xue N; Lai F; Du T; Ji M; Liu D; Yan C; Zhang S; Yu X; Jin J; Chen X
Cell Mol Life Sci; 2019 Sep; 76(17):3433-3447. PubMed ID: 30980109
[TBL] [Abstract][Full Text] [Related]
5. HER3-Mediated Resistance to Hsp90 Inhibition Detected in Breast Cancer Xenografts by Affibody-Based PET Imaging.
Martins CD; Da Pieve C; Burley TA; Smith R; Ciobota DM; Allott L; Harrington KJ; Oyen WJG; Smith G; Kramer-Marek G
Clin Cancer Res; 2018 Apr; 24(8):1853-1865. PubMed ID: 29437790
[No Abstract] [Full Text] [Related]
6. NIX protein enhances antioxidant capacity of and reduces the apoptosis induced by HSP90 inhibitor luminespib/NVP-AUY922 in PC12 cells.
Zhang H; Ge F; Shui X; Xiang Y; Wang X; Liao C; Wang J
Cell Stress Chaperones; 2021 May; 26(3):495-504. PubMed ID: 33629253
[TBL] [Abstract][Full Text] [Related]
7. A repurposing strategy for Hsp90 inhibitors demonstrates their potency against filarial nematodes.
Gillan V; O'Neill K; Maitland K; Sverdrup FM; Devaney E
PLoS Negl Trop Dis; 2014 Feb; 8(2):e2699. PubMed ID: 24551261
[TBL] [Abstract][Full Text] [Related]
8. Inhibition of HSP90 overcomes melphalan resistance through downregulation of Src in multiple myeloma cells.
Tabata M; Tsubaki M; Takeda T; Tateishi K; Maekawa S; Tsurushima K; Imano M; Satou T; Ishizaka T; Nishida S
Clin Exp Med; 2020 Feb; 20(1):63-71. PubMed ID: 31650359
[TBL] [Abstract][Full Text] [Related]
9. Heat shock protein 90 (HSP90) inhibitors in gastrointestinal cancer: where do we currently stand?-A systematic review.
Magyar CTJ; Vashist YK; Stroka D; Kim-Fuchs C; Berger MD; Banz VM
J Cancer Res Clin Oncol; 2023 Aug; 149(10):8039-8050. PubMed ID: 36966394
[TBL] [Abstract][Full Text] [Related]
10. Understanding the Hsp90
Magwenyane AM; Mhlongo NN; Lawal MM; Amoako DG; Somboro AM; Sosibo SC; Shunmugam L; Khan RB; Kumalo HM
Molecules; 2020 Apr; 25(8):. PubMed ID: 32295059
[TBL] [Abstract][Full Text] [Related]
11. HSP90 inhibition acts synergistically with heat to induce a pro-immunogenic form of cell death in colon cancer cells.
Mouratidis PXE; Ter Haar G
Int J Hyperthermia; 2021; 38(1):1443-1456. PubMed ID: 34612127
[TBL] [Abstract][Full Text] [Related]
12. Development of VER-50589 analogs as novel Hsp90 inhibitors.
Fang X; Feng J; Wang K; Luan Y
Bioorg Med Chem Lett; 2023 Jul; 91():129375. PubMed ID: 37315698
[TBL] [Abstract][Full Text] [Related]
13. Comprehensive analysis of resorcinyl-imidazole Hsp90 inhibitor design.
Gedgaudas M; Kaziukonytė P; Kairys V; Mickevičiūtė A; Zubrienė A; Brukštus A; Matulis D; Kazlauskas E
Eur J Med Chem; 2024 Jul; 273():116505. PubMed ID: 38788300
[TBL] [Abstract][Full Text] [Related]
14. Inhibiting heat shock protein 90 (HSP90) limits the formation of liver cysts induced by conditional deletion of Pkd1 in mice.
Smithline ZB; Nikonova AS; Hensley HH; Cai KQ; Egleston BL; Proia DA; Seeger-Nukpezah T; Golemis EA
PLoS One; 2014; 9(12):e114403. PubMed ID: 25474361
[TBL] [Abstract][Full Text] [Related]
15. COTI-2, a novel small molecule that is active against multiple human cancer cell lines in vitro and in vivo.
Salim KY; Maleki Vareki S; Danter WR; Koropatnick J
Oncotarget; 2016 Jul; 7(27):41363-41379. PubMed ID: 27150056
[TBL] [Abstract][Full Text] [Related]
16. Heat-activated nanomedicine formulation improves the anticancer potential of the HSP90 inhibitor luminespib in vitro.
Epp-Ducharme B; Dunne M; Fan L; Evans JC; Ahmed L; Bannigan P; Allen C
Sci Rep; 2021 May; 11(1):11103. PubMed ID: 34045581
[TBL] [Abstract][Full Text] [Related]
17. Multiomic-Based Molecular Landscape of FaDu Xenograft Tumors in Mice after a Combinatorial Treatment with Radiation and an HSP90 Inhibitor Identifies Adaptation-Induced Targets of Resistance and Therapeutic Intervention.
Bylicky MA; Shankavaram U; Aryankalayil MJ; Chopra S; Naz S; Sowers AL; Choudhuri R; Calvert V; Petricoin EF; Eke I; Mitchell JB; Coleman CN
Mol Cancer Ther; 2024 Apr; 23(4):577-588. PubMed ID: 38359816
[TBL] [Abstract][Full Text] [Related]
18. Finding Integrative Medication for Neuroblastoma and Glioblastoma through Zebrafish as A Model of Organism.
Barati M; Chahardehi AM; Hosseini Y
Curr Top Med Chem; 2023; 23(30):2807-2820. PubMed ID: 37861004
[TBL] [Abstract][Full Text] [Related]
19. Design, synthesis, and biological activity of dual monoamine oxidase A and heat shock protein 90 inhibitors, N-Methylpropargylamine-conjugated 4-isopropylresorcinol for glioblastoma.
Tseng HJ; Banerjee S; Qian B; Lai MJ; Wu TY; Hsu TI; Lin TE; Hsu KC; Chuang KH; Liou JP; Shih JC
Eur J Med Chem; 2023 Aug; 256():115459. PubMed ID: 37172473
[TBL] [Abstract][Full Text] [Related]
20. Natural Products Targeting Hsp90 for a Concurrent Strategy in Glioblastoma and Neurodegeneration.
Mitra S; Dash R; Munni YA; Selsi NJ; Akter N; Uddin MN; Mazumder K; Moon IS
Metabolites; 2022 Nov; 12(11):. PubMed ID: 36422293
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
